Cellectar Biosciences, Inc. (CLRB) stock
Close on Nov 11, 2026Market cap $11.44MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $11.44M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.51
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$25.85M
- EPS, diluted
- -$8.35
- Free cash flow
- -$23.12M
- Book value per share
- $1.28
- Diluted shares
- 17M
Trading
- Next earnings
- Mar 3, 2027 (estimated, before the open)
- Previous close
- $1.22
- Open
- $1.26
- Day's range
- $1.19 – $1.30
- Volume
- 21,470
- Average volume (20 days)
- 129,580
- Beta (5 years)
- 1.66
- 52-week range
- $1.11 – $4.70
- RSI (14 days)
- 38.9
- Volatility (1 year)
- 79.1%
- Relative volume
- 0.24×
- WACC
- 13.2%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CLRB | S&P 500 | Difference | CLRB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -16.6% | -2.4% | −14.1 pts | ||
| 3 months | -54.2% | -1.2% | −53.0 pts | ||
| Year to date | -59.0% | +12.3% | −71.3 pts | ||
| 1 year | -66.0% | +12.4% | −78.5 pts | ||
| 3 years | -97.9% | +78.8% | −176.7 pts | -72.5% | +21.4% |
| 5 years | -99.5% | +75.2% | −174.7 pts | -65.8% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -57.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cellectar Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Cellectar Biosciences
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical firm that develops targeted cancer therapies using a proprietary phospholipid ether drug conjugate platform. Its research pipeline centers on phospholipid radioconjugates that deliver radioactive isotopes directly into malignant cells while sparing healthy tissue. Key product candidates include iopofosine I 131, a beta-emitting agent evaluated for blood cancers, alongside preclinical and early clinical programs CLR 125 and CLR 225, which utilize Auger and alpha radiation for solid tumors. The firm primarily serves cancer patients, targeting adult and pediatric populations diagnosed with conditions such as Waldenstrom macroglobulinemia, multiple myeloma, central nervous system lymphoma, and rare solid tumors.
Company profile, executives and historyCellectar Biosciences stock: common questions
What is Cellectar Biosciences's stock price?
CLRB closed at $1.21 on Nov 11, 2026, down 0.82% on the day. Over the past 52 weeks it traded between $1.11 and $4.70.
What is Cellectar Biosciences's market cap?
Cellectar Biosciences was worth $11.44M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CLRB's P/E ratio?
Cellectar Biosciences lost money over fiscal 2025 (diluted EPS -$8.35), so it has no meaningful P/E ratio.
Does Cellectar Biosciences pay a dividend?
No. Cellectar Biosciences has not paid a cash dividend over the last twelve months.
When does Cellectar Biosciences report earnings next?
Cellectar Biosciences is expected to report Q4 FY2026 results on Mar 3, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CLRB stock performed over the past year?
Including dividends, CLRB returned -66.0% over the past year, against +12.4% for the S&P 500.
How many CLRB shares are sold short?
0M shares were sold short at the latest FINRA report, 2.34% of the float, or 1.6 days of average trading volume.
Who are Cellectar Biosciences's competitors?
Companies most similar to Cellectar Biosciences by business, industry and size include IMNM, SLS, ATNM, PYXS, AKTS.
See a number that looks wrong?